Chief Investment Officer, KIS Capital Partners

Josh Best

Chief Investment Officer

Boutique absolute return fund manager

KIS Capital Partners

KIS Capital Partners is a boutique absolute return fund manager based in Sydney, Australia with an Asia ex Japan trading focus. We believe that an absolute return fund should be risk and performance focused with strong attention to investment differentiation. Absolute return funds should not be asset gatherers. We invest alongside our clients in liquid and transparent markets with a focus on pragmatic and vigilant risk management.

Thematic (Sector/Industry)

<p>At KIS capital we try to keep ourselves at the forefront of technology and innovation, attempting to identify which industries may blossom, and which may be disrupted. In the middle of 2016, KIS Research published its in-depth report on Autonomous Vehicles. That paper proved to be well ahead of the curve, with autonomous cars and electric vehicles becoming an important investment theme over the last year. To follow up the success of that report, we have released this one, focusing on a new topic: human longevity. We see human longevity as a huge new investment theme. Whilst its impact on the healthcare system alone will be enormous, we expect its ripples to extend further, washing into the broader economy. Human longevity will create a more productive working age population, extend the retirement age, create new consumer spending patterns amongst the elderly, cause a revamp of the superannuation system, increase unfunded pension liabilities, change life and health insurance premiums, and even alter the way in which fiscal policy is managed, to name a few. In this report we will explore the burgeoning technologies that are seeking to extend healthy life well north of 100 years (NB: there is a section on life hacks that you can be doing today to increase your longevity). If this investment theme is of further interest to you, get in touch with us!</p>

At KIS capital we try to keep ourselves at the forefront of technology and innovation, attempting to identify which industries may blossom, and which may be disrupted. In the middle of 2016, KIS Research published its in-depth report on Autonomous Vehicles. That paper proved to be well ahead of the curve, with autonomous cars and electric vehicles becoming an important investment theme over the last year. To follow up the success of that report, we have released this one, focusing on a new topic: human longevity. We see human longevity as a huge new investment theme. Whilst its impact on the healthcare system alone will be enormous, we expect its ripples to extend further, washing into the broader economy. Human longevity will create a more productive working age population, extend the retirement age, create new consumer spending patterns amongst the elderly, cause a revamp of the superannuation system, increase unfunded pension liabilities, change life and health insurance premiums, and even alter the way in which fiscal policy is managed, to name a few. In this report we will explore the burgeoning technologies that are seeking to extend healthy life well north of 100 years (NB: there is a section on life hacks that you can be doing today to increase your longevity). If this investment theme is of further interest to you, get in touch with us!

Netherlands

QIAGEN N.V. is a global provider of Sample to Insight solutions to transform biological materials into valuable molecular insights. The Company provides its workflows to customers in Molecular Diagnostics (human healthcare), Applied Testing (forensics, veterinary testing and food safety), Pharma (pharmaceutical and biotechnology companies) and Academia (life sciences research).

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Qiagen N.V. (QGEN US)

Human Longevity

At KIS capital we try to keep ourselves at the forefront of technology and innovation, attempting to identify which industries may blossom, and...

KIS Capital Partners

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)